Dupixent (Sanofi and Regeneron) is expected to face US biosimilar competition from 2031. Extended US patent runs to 28 March 2031. Sanofi plans to defend exclusivity beyond that.
Dupixent's US exclusivity date is based on company guidance. The date comes from the company's own filings or guidance. Secondary patents, new formulations or litigation can still move it. It is a biologic, so copies are biosimilars. Biosimilars are harder to make and usually erode sales more gradually than generics.
Dupixent is 36% of Sanofi's 2025 revenue (≈$17.8B of $49.3B). Total net sales €43.6B. Sanofi books Dupixent's global sales.
Dupixent is 37% of Regeneron's 2025 revenue ($5.2B of $14.3B). Dupixent is Regeneron's Sanofi collaboration revenue ($5.2B), mostly its share of Dupixent profits.
Bars show each company's tracked drugs as a share of its total 2025 revenue. Dupixent is highlighted.